Heathy Participants Clinical Trial
Official title:
A Randomised, Single-blind, Single Center, Placebo-controlled, Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD7503 Following Multiple Subcutaneous Dose Administration in Healthy Japanese Participants.
Verified date | April 2024 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The study will evaluate the safety, tolerability, and the pharmacokinetics (PK) of AZD7503 following multiple subcutaneous doses in healthy Japanese participants.
Status | Completed |
Enrollment | 12 |
Est. completion date | March 20, 2024 |
Est. primary completion date | March 20, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - For Japanese participants: A Japanese participant is defined as having both parents and 4 Japanese grandparents as confirmed by the interview. This includes second and third generation Japanese whose parents or grandparents are living in a country other than Japan. Participants must have suitable veins for cannulation. - Females must be of non-childbearing potential. - Males and females must adhere to the contraception methods. - Have a Body mass index between 18 and 30 kg/m2 inclusive. Exclusion Criteria: - History of any clinically significant disease or disorder in the investigator's opinion. - History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. - Any clinically important illness, medical/surgical procedure or trauma. - Any abnormal laboratory values, clinical chemistry, hematology or urinalysis results, vital signs, Electrocardiography. - Any clinically significant cardiovascular event. - Participants with known autoimmune disease or on-treatment with immune-modulatory drugs. - Any positive result at the Screening Visit for serum Hepatitis B surface antigen, hepatitis C antibody and Human Immunodeficiency virus. - Confirmed COVID-19 infection during screening as per local guidelines. - History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity. - Use of any prescribed or nonprescribed medication. - History of major bleed or high-risk of bleeding diathesis. - Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of study intervention. - Participants who have previously received AZD7503 or any investigational drug targeting HSD17B13. - Vulnerable participants. |
Country | Name | City | State |
---|---|---|---|
Japan | Research Site | Sumida-ku |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with adverse events | The safety and tolerability after multiple doses of AZD7503 in healthy Japanese participants will be evaluated. | From Screening (Day -28) until Follow-up Day 127 (10 weeks post last dose) | |
Secondary | Maximum plasma drug concentration (Cmax) | The Cmax after administration of multiple doses of AZD7503 in healthy Japanese participants will be evaluated. | Day 1, Day 2, Day 3, Day 5, Day 15, Day 29, Day 57, Day 58, and Day 59 | |
Secondary | Are under plasma concentration-time curve from time 0 to the last quantifiable concentration (AUClast) | The AUClast after administration of multiple doses of AZD7503 in healthy Japanese participants will be evaluated. | Day 1, Day 2, Day 3, Day 5, Day 15, Day 29, Day 57, Day 58, and Day 59 | |
Secondary | Area under plasma concentration-time curve from time 0 to infinity (AUCinf) | The AUCinf after administration of multiple doses of AZD7503 in healthy Japanese participants will be evaluated. | Day 1, Day 2, Day 3, Day 5, Day 15, Day 29, Day 57, Day 58, and Day 59 | |
Secondary | Area under plasma concentration-time curve during a dosing interval (AUCtau) | The AUCtau after administration of multiple doses of AZD7503 in healthy Japanese participants will be evaluated. | Day 1, Day 2, Day 3, Day 5, Day 15, Day 29, Day 57, Day 58, and Day 59 | |
Secondary | Amount of analyte excreted into the urine (Ae) | The Ae after administration of multiple doses of AZD7503 in healthy Japanese participants will be evaluated. | Day 1, Day 2, Day 3, Day 58, and Day 59 | |
Secondary | Fraction of the dose excreted unchanged in urine (Fe) | The Fe after administration of multiple doses of AZD7503 in healthy Japanese participants will be evaluated. | Day 1, Day 2, Day 3, Day 58, and Day 59 | |
Secondary | Plasma concentration of AZD7503 | The plasma concentration after administration of multiple doses of AZD7503 in healthy Japanese participants will be evaluated. | Day 1, Day 2, Day 3, Day 58, and Day 59 | |
Secondary | Plasma concentration of unconjugated antisense oligonucleotide (ASO) | The plasma concentration of unconjugated ASO at specified timepoints after administration of multiple doses of AZD7503 in healthy Japanese participants will be evaluated. | Day 1, Day 2, Day 3, Day 58, and Day 59 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04090047 -
A Study to Investigate the Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of PF-06700841 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT06139991 -
Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.
|
Phase 1 |